Extended HPV Genotyping in Risk-Based Cervical Cancer Screening: Insights from WHO Recommendations

The WHO recommendations for HPV DNA-based cervical cancer screening emphasize a risk-based approach, recognizing that different carcinogenic HPV (cHPV) genotypes carry different levels of cervical cancer risk.

WHO highlights the importance of identifying key carcinogenic HPV genotypes for more informed clinical management, including:

• HPV16
• HPV18, HPV45
• HPV31, HPV33, HPV35, HPV52, HPV58
• HPV39, HPV51, HPV56, HPV59

In settings with sufficient follow-up capacity and treatment resources, WHO supports extended HPV genotyping strategies to enable more precise risk stratification:

✔ Higher-risk HPV genotypes such as HPV16, HPV18, HPV45, HPV31, HPV33, HPV35, HPV52 and HPV58 may support more direct clinical management pathways.

✔ Other carcinogenic HPV genotypes, including HPV39, HPV51, HPV56 and HPV59, may require additional triage evaluation.

By providing more detailed genotype information, extended HPV genotyping helps support evidence-based cervical cancer screening strategies.

What does this mean for laboratories?

As screening programs move toward more genotype-guided management, laboratories require flexible HPV testing solutions that support different clinical workflows.

Cowingene provides HPV molecular diagnostic solutions across NATBox Molecular POCT and Real-Time PCR platforms, covering different testing needs from routine HPV detection to extended genotyping and broader HPV characterization.

Explore Cowingene HPV solutions for your cervical cancer screening workflow.

Click to view the LinkedIn post

(https://www.linkedin.com/feed/update/urn:li:activity:7485609234752020481)